Changchun GeneScience Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05673694
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Cancer Hospital of CAMS, Beijing, Benjing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
GS3-007a Oral Solution in Healthy Subjects
- Conditions
- Healthy Subject
- Interventions
- Drug: GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05611281
- Locations
- 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Chengdu, China
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05441046
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05353192
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Clinical Study of Genakumab for Injection in Patients With Acute Gout
- Conditions
- Acute Gout
- Interventions
- Drug: Genakumab for InjectionDrug: Placebo for Genakumab for Injection
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 121
- Registration Number
- NCT05328531
- Locations
- 🇨🇳
Shanghai Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05263271
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05223595
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05221385
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Jian Zhang, Shanghai, Shanghai, China
Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: Placebo for this trial
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04337437
- Locations
- 🇨🇳
Clinical Pharmacology Research Center of Peking Union Medical College Hospital, Beijing, China
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
- Conditions
- Advanced Gastric or Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT04053205
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Fujian Tumor Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China